Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://margarety803eyu1.blogoscience.com/profile